Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

BACKGROUND: Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate whether the reported differences in the efficacy and toxicity of monotherapy with doxorubicin (DOX) versus combination therapy with cisplatin (...

Full description

Bibliographic Details
Main Author: Aapro, MS (author)
Other Authors: Van Wijk, FH (author), Bolis, G (author), Chevallier, B (author), Van der Burg, ME (author), Oliveira, CF (author)
Format: article
Language:eng
Published: 2008
Subjects:
Adenocarcinoma
Cisplatina
Doxorubicina
Neoplasias do Endométrio
Online Access:http://hdl.handle.net/10400.4/126
Country:Portugal
Oai:oai:rihuc.huc.min-saude.pt:10400.4/126

Internet

http://hdl.handle.net/10400.4/126

Similar Items